Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective.
about
Information and communication technology based prompting for treatment compliance for people with serious mental illnessInformation and communication technology based prompting for treatment compliance for people with serious mental illnessCan the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as ExamplesResource utilization and cost in a commercially insured population with schizophreniaA patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophreniaImpact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysisEfficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaSwitching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database.Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People's Republic of ChinaThe ethics of elective psychopharmacologyTreatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophreniaProbing thalamic integrity in schizophrenia using concurrent transcranial magnetic stimulation and functional magnetic resonance imaging.Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model.Conserved functional connectivity but impaired effective connectivity of thalamocortical circuitry in schizophrenia.Burden of treatment for chronic illness: a concept analysis and review of the literature.Review of international early psychosis programmes and a model to overcome unique challenges to the treatment of early psychosis in the United States.Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain.The Cost of Relapse in Schizophrenia.Twelve-Month Health Care Use and Mortality in Commercially Insured Young People With Incident Psychosis in the United States.Rural and remote early psychosis intervention services: the Gordian knot of early intervention.Common variants of HTR1A and SLC6A4 confer the increasing risk of Schizophrenia susceptibility: A population-based association and epistasis analysis.Factors in Maintaining a Stable Patient-Physician Relationship among Individuals with Schizophrenia.Predictors for clinical deterioration of mental state in patients assessed by telephone-based mental health triage.Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States.Claims-based proxies of patient instability among commercially insured adults with schizophrenia.Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis
P2860
Q24193953-311F771C-1E7D-46DB-83E6-56B46BFB2D97Q24202535-FEA44F47-8BBA-4F23-A23C-197E2CDC0EE0Q26774170-789DD577-9B81-4B96-AEDE-91C4CAC52DCAQ33652933-5332F43B-3C15-46EA-8E82-633FC2650496Q34203368-5011551D-622E-4409-97E7-2C83183A47B6Q34982167-785D89C9-85F1-4CAD-8DCE-5864AFDCB687Q35186007-F49D5C59-B89C-4C22-95D5-F58B9E2DBBB5Q35249595-E6DEEE9B-7B18-4FBA-8BBD-37B19E639AF5Q35427820-B877E8E5-116B-471F-BBC4-639A8152C8F8Q35886546-2959B36E-9E60-4964-9FC0-C05C8086F227Q35948848-E4EFD86A-9D15-4FF6-8A03-9600248F50D5Q36139891-FC2F3ED9-351D-41EA-B071-6E06EE45E5BCQ36445106-CD7F3E4A-386C-41F1-ABCE-7AAFF32E9B93Q36752637-10C54D5A-AD61-4627-B067-093B2307A52AQ37333252-FDB0D490-9242-4E95-A577-E2541DAB1C33Q38191701-458FF331-936A-4590-AB06-84CAD8A6A16DQ38692993-3C746CD4-099C-434D-B461-B35F88AEBBB8Q38769604-8838BAB6-B269-4228-B91C-7115D54714FAQ38842576-0E74238A-DC6F-4460-9197-878AEEA3EBCCQ39387296-2AF026E8-8088-4580-899A-151EB4EDD912Q41312111-1CB701B1-0C3C-4D93-8E70-3C82311532ACQ47779788-895FB11F-80A8-4052-942D-FA754416E9F5Q47902183-5EFA3E04-3CA7-4BD8-9A8A-66DB44C65ADEQ47998008-3182A577-9FA4-4E18-BF48-376EEE727F8BQ55161186-43604595-6C5A-4FFC-B348-A83C8B7EC692Q55324826-80D0B2BE-34D5-4503-BB51-DABD47D13ACCQ58763260-DB5D0BFB-AA43-486D-BE57-F668D08D4855
P2860
Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Burden of schizophrenia in rec ...... lisation and cost perspective.
@en
Burden of schizophrenia in rec ...... lisation and cost perspective.
@nl
type
label
Burden of schizophrenia in rec ...... lisation and cost perspective.
@en
Burden of schizophrenia in rec ...... lisation and cost perspective.
@nl
prefLabel
Burden of schizophrenia in rec ...... lisation and cost perspective.
@en
Burden of schizophrenia in rec ...... lisation and cost perspective.
@nl
P2093
P1476
Burden of schizophrenia in rec ...... lisation and cost perspective.
@en
P2093
Deborah Nicholl
Jan Schadrack
Joris Diels
Kasem S Akhras
P304
P356
10.1185/03007991003658956
P407
P577
2010-04-01T00:00:00Z